Want to see CLDX full AI Analyst Report?
Top Page
Celldex
(NASDAQ:CLDX)
Select Model
Select Model
Rating:51Neutral
Price Target:
$31.00
▼(-23.59% Downside)
Action:Reiterated
Date:09/24/26
The score is held back primarily by weak financial performance (widening losses, near-zero TTM revenue, and accelerating cash burn) and bearish technical trends (below major moving averages with negative MACD). Offsetting these risks are a strong, low-debt balance sheet and a major positive corporate catalyst from strong Phase 3 trial results.
Positive Factors
Phase 3 clinical validation
Strong Phase 3 results materially improve barzolvolimab’s development and potential commercialization outlook. Efficacy across difficult-to-treat patients, sustained responses, and favorable safety support regulatory progress and increase the program’s strategic importance over the next several quarters.
Negative Factors
Limited commercial revenue
Near-zero trailing revenue indicates Celldex is not yet supported by a durable commercial product base. Continued reliance on financing, collaborations, or other non-recurring sources can constrain operating independence and make future investment capacity dependent on external funding conditions.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 3 clinical validation
Strong Phase 3 results materially improve barzolvolimab’s development and potential commercialization outlook. Efficacy across difficult-to-treat patients, sustained responses, and favorable safety support regulatory progress and increase the program’s strategic importance over the next several quarters.
Read all positive factors
Celldex (CLDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.53B
Dividend YieldN/A
Average Volume (3M)1.49M
Price to Earnings (P/E)―
Beta (1Y)1.42
Revenue Growth-97.27%
EPS Growth-44.90%
CountryUS
Employees198
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.36
Shares Outstanding78,529,530
10 Day Avg. Volume3,171,337
30 Day Avg. Volume1,485,912
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)3.43
Price to Sales (P/S)1204.09
P/FCF Ratio-8.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue0.02
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$65.25Price Target Upside60.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-4.13
Revenue Forecast (FY)$1.69M
Celldex Business Overview & Revenue Model
Company Description
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both i...
How the Company Makes Money
Celldex does not primarily generate revenue from selling marketed drugs; instead, as a clinical-stage biotech, it funds operations mainly through financing activities and, when applicable, collaboration-related income. Material sources of cash and...
Celldex Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
82
Very Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 112.00K | 1.50M | 7.02M | 6.88M | 2.36M | 4.65M |
| Gross Profit | -63.67M | 1.50M | -156.53M | -111.13M | -79.90M | -48.66M |
| EBITDA | -297.20M | -255.42M | -154.69M | -139.03M | -104.20M | -66.08M |
| Net Income | -300.59M | -258.80M | -157.86M | -141.43M | -112.33M | -70.51M |
Balance Sheet | ||||||
| Total Assets | 782.35M | 582.98M | 792.34M | 465.63M | 352.74M | 444.65M |
| Cash, Cash Equivalents and Short-Term Investments | 717.59M | 518.57M | 725.28M | 421.70M | 304.95M | 408.25M |
| Total Debt | 4.90M | 2.34M | 3.81M | 2.54M | 4.03M | 3.04M |
| Total Liabilities | 67.78M | 55.82M | 45.34M | 36.46M | 26.53M | 25.18M |
| Stockholders Equity | 714.56M | 527.16M | 747.00M | 429.17M | 326.20M | 419.48M |
Cash Flow | ||||||
| Free Cash Flow | -241.82M | -213.66M | -159.70M | -109.11M | -105.56M | -62.16M |
| Operating Cash Flow | -235.57M | -210.94M | -157.78M | -107.29M | -103.73M | -60.91M |
| Investing Cash Flow | -67.13M | 209.07M | -290.13M | -105.78M | 89.94M | -216.16M |
| Financing Cash Flow | 327.11M | 2.39M | 441.45M | 218.46M | 4.08M | 272.37M |
Celldex Technical Analysis
Negative
40.57
Price Trends
38.29
Negative
35.88
Negative
32.33
Negative
Market Momentum
-2.10
Positive
30.59
Neutral
16.64
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDX, the sentiment is Negative. The current price of 40.57 is above the 20-day moving average (MA) of 35.53, above the 50-day MA of 38.29, and above the 200-day MA of 32.33, indicating a bearish trend. The MACD of -2.10 indicates Positive momentum. The RSI at 30.59 is Neutral, neither overbought nor oversold. The STOCH value of 16.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLDX.
Celldex Risk Analysis
Celldex disclosed 2 risk factors in its most recent earnings report. Celldex reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Celldex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $6.45B | -20.31 | -40.51% | ― | 34.52% | 41.20% | |
62 Neutral | $1.96B | -11.83 | -49.73% | ― | 1083.56% | 30.89% | |
59 Neutral | $2.42B | -6.66 | -76.09% | ― | -58.40% | -31.99% | |
52 Neutral | $2.37B | -8.23 | -50.56% | ― | -100.00% | 18.12% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.53B | -7.26 | -52.36% | ― | -97.27% | -44.90% | |
50 Neutral | $1.60B | -6.50 | -37.99% | ― | -27.15% | 23.10% |
* Healthcare Sector Average
CLDX
Celldex
31.65
5.24
19.84%
NKTR
Nektar Therapeutics
43.58
-16.97
-28.03%
IOVA
Iovance Biotherapeutics
14.22
11.88
507.48%
NRIX
Nurix Therapeutics
22.99
13.61
145.10%
NUVB
Nuvation Bio
5.14
1.43
38.54%
IMNM
Immunome
20.90
8.52
68.82%
Celldex Corporate Events
Business Operations and StrategyProduct-Related Announcements
Celldex reports strong Phase 3 data in urticaria
Positive
Sep 22, 2026
On September 22, 2026, Celldex reported positive topline data from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab in chronic spontaneous urticaria patients inadequately controlled by H1-antihistamines. Both studies, which together...
Business Operations and StrategyShareholder Meetings
Celldex Shareholders Approve Expanded Equity Incentive Plan
Positive
Jun 26, 2026
At its June 25, 2026 annual meeting, Celldex Therapeutics stockholders approved an amendment to the company’s 2021 Omnibus Equity Incentive Plan, increasing the shares available for issuance by 3,400,000 to a total of 12,900,000 and clarifyi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.